Assessment of efficacy of ticagrelor versus clopidogrel in the treatment of myocardial infarction by 2D echocardiography

Marina Gladys D’ Souza; Aishwarya Goud Muthyala; Tejaswini Myaka; Sanjib Kumar Sahu; Swathi Boddupalli

doi:10.30574/gscbps.2020.12.3.0256

Authors

Marina Gladys D’ Souza Bharat Institute of technology, Department of Pharmacognosy, Mangalpally, Ibrahimpatnam, Hyderabad, India – 501510.
Aishwarya Goud Muthyala Bharat Institute of technology, Department of Pharmacognosy, Mangalpally, Ibrahimpatnam, Hyderabad, India – 501510.
Tejaswini Myaka Bharat Institute of technology, Department of Pharmacognosy, Mangalpally, Ibrahimpatnam, Hyderabad, India – 501510.
Sanjib Kumar Sahu Pharm D-V year, Department of Pharm D, Bharat School of pharmacy, Mangalpally, Ibrahimpatnam, Hyderabad, India- 501510.
Swathi Boddupalli Assistant professor, Department of Pharm D, Bharat School of pharmacy, Mangalpally, Ibrahimpatnam, Hyderabad, India- 501510.

DOI:

https://doi.org/10.30574/gscbps.2020.12.3.0256

Keywords:

Myocardial infarction, Anti-platelet, Ticagrelor, clopidogrel, 2D echo

Abstract

Myocardial infarction (MI) is the irreversible death of heart muscle due to prolonged lack of supply of oxygen resulting in decreased coronary blood flow and if untreated may lead to myocardial damage. Myocardial infarction may be due to several causes viz., coronary occlusion, ventricular hypertrophy, coronary artery emboli or coronary trauma. Drugs used for the treatment of MI includes vasodilators to dilate the arteries and veins, antiarrythmics, thrombolytics to dissolve clots, anti-thrombolytics to prevent thrombus formation, anti-platelet drugs, analgesics to reduce pain, cardiac depressants to control heart rate and contractions. Present study was undertaken to evaluate the efficacy of Ticagrelor v/s Clopidogrel the antiplatelet drugs indicated in patients to reduce the risk of myocardial infarction. Both the drugs act by preventing the formation of platelet clots and helps in the smooth flow of blood. Assessment of results was carried out by 2d Echo test to evaluate the efficacy of the treatment. Treatment with ticagrelor showed improved efficacy and safety by improving the ejection fraction, reducing the rate of stroke, reducing vascular abnormalities, showing no bleeding problems. No death is observed due to vascular problems in both the treatment. Ticagrelor revealed considerable recovery rate compared to clopidogrel. Study reports revealed that ticagrelorisefficient thanclopidogrel in the treatment of MI and is a better choice over clopidogrel to treat MI.

Metrics

Metrics Loading ...

References

Saleh M, Ambrose JA.(2019). Understanding myocardial infarction. F1000 Research, 7:1000 Faculty Rev, 1378.

Thomas FLüscher. (2015). Myocardial infarction mechanisms, diagnosis, and complications. European Heart Journal, 36(16), 947-949.

Ezra A. Amsterdam, Nanette K. Wenger, Ralph G. Brindis, Donald E. CaseyJr, Theodore G. Ganiats et.al. (2014). 2014 AHA/ACC Guideline for the management of patients with non–ST-Elevation acute coronary syndromes. Circulation, 130(25), 344–426.

Maxwell S. (1999). Emergency management of acute myocardial infarction. British journal of clinical pharmacology, 48(3), 284–298.

Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. (2014). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke, 45(7), 2160–2236.

Greaves SC. (2002). Role of echocardiography in acute coronary syndromes. Heart, 88(4), 419–425.

Massberg S, Polzin A. (2018). Dual Antiplatelet Therapy. Dtsch. Med. Wochenschr, 143(15), 1090-1093.

Komosa A, Lesiak M, Siniawski A, Mularek-Kubzdela T, Grajek S. (2014). Significance of antiplatelet therapy in emergency myocardial infarction treatment. Advances in interventional cardiology, 10(1), 32.

Alizadehasl A, Sadeghpour A, Behjati M. (2017). The role of echocardiography in acute myocardial infarction. Indian heart journal, 69(4), 563.

Layne K, Ferro A. (2017). Antiplatelet Therapy in Acute Coronary Syndrome. European cardiology, 12(1), 33–37.